Who makes Dipyridamole 200 mg?

Dipyridamole 200 mg is developed by Vastra Gotaland Region.

What development phase is Dipyridamole 200 mg in?

Dipyridamole 200 mg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Dipyridamole 200 mg

Vastra Gotaland Region · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Dipyridamole 200 mg
Sponsor	Vastra Gotaland Region
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Aggrenox To Treat Acute Covid-19 (PHASE3)
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome. (PHASE4)
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19 (PHASE2)
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation (PHASE2)
Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (PHASE3)
Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) (NA)
Accuracy of Half of the Usual Radiotracer Dose in SPECT (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dipyridamole 200 mg CI brief — competitive landscape report
Dipyridamole 200 mg updates RSS · CI watch RSS
Vastra Gotaland Region portfolio CI